Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07039513
Starting soon Observational

EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO

NCT07039513 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2025-11-27
Last updated
2025-12-01

Condition(s) studied

ECMOMplementation of a Veno-venous VV or Veno-arterial VAINTENSIVE CARE

Investigational drug(s) / intervention(s)

Blood sampling collection

Blood sampling collection: Collection of an additional of 2.7mL citrate tube of blood for a D-dimer dosage.

Study summary

ECMO (extracorporeal membrane oxygenation) is a life-saving device, used in intensive care to treat severe respiratory or cardiac failure. However, it carries a high risk of serious life-threatening bleeding.

Bleeding complications have been attributed to coagulopathy triggered either by the underlying pathology or by the extracorporeal circuit itself, as well as excessive or inappropriate anticoagulation initiated to prevent thrombotic complications.

The objective of this cohort is to confirm the interest of the evolution of D-dimers as a prognostic marker of serious bleeding events in patients on veno-venous (VV) or veno-arterial (VA) ECMO, and to determine the threshold.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female ≥ 18 years of age * Hospitalized patient in intensive care * Implementation of a VV or VA ECMO for less than 24 hours * Patient affiliated to a social protection health insurance scheme * Non-opposition by the patient or a relative in the event that the patient is not in a state to express his or her non-opposition or inclusion in an emergency procedure in the event that the patient is not in a state to express his or her non-opposition and no relative of the patient can be reached. Exclusion Criteria: * Patient on veno-arterial ECMO after cardiac, cardiopulmonary surgery or after placement of a left or biventricular cardiac assist device * Congenital hemostasis disorder or anatomical abnormality predisposing to bleeding * Dying patient on the day of inclusion * Patient under judicial protection * Patient under guardianship or curatorship * Pregnancy * Breastfeeding

Primary outcome measure(s)

  • To determine the most discriminating 24-hour D-Dimer increase threshold for predicting a serious bleeding event under ECMO within 24 hours of D-Dimer increase — 1 month
    Difference in D-dimer over 24 hours associated with the occurrence of severe bleeding within 24 hours.

Trial sites (1)

FacilityCityRegionStatus
Service de Médecine Intensive - Réanimation Nouvel Hôpital Civil Strasbourg France

More University Hospital, Strasbourg, France trials in France

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers Active, not recruiting
Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease Recruiting
Impact of Perioperative Organ Resuscitation of Brain-dead Deceased Organ Donor on Kidney Graft Function in the Recipient Recruiting
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025 Recruiting

Other trials for the same condition

Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults Recruiting
Lung Recruitment During Chest Physiotherapy in Mechanically Ventilated Patients Recruiting
Implicit Bias in Intensive Care: Analysis and Assessment. Starting soon
Kinetics of INF-γ Production in Intensive Care Patients Recruiting
Development and Validation of a Mouth Assessment Tool for Orally Intubated Patients in Intensive Care Unit) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07039513 on ClinicalTrials.gov ↗ ← All trials in France